~~<i id='5FB1AE4D66'><strike id='5FB1AE4D66'><tt id='5FB1AE4D66'><pre id='5FB1AE4D66'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：hotspot 2025-08-22 18:30:34 - browse：655

An illustration of red blood cells — Adobe

As a boy growing up with hemophilia A, Noah Frederick reserved the end of his annual checkups to talk about new technologies. His doctor walked through various experimental approaches for the bleeding disorder and, invariably, gene therapy. It was coming, he always said, in your lifetime.

Last year, it finally arrived. But Frederick, now a 23-year-old software engineer, isn’t sure he’ll get it. He wants to be part of the sci-fi future gene therapy has always represented, but a recent doctor’s visit left him uncertain.

“I’m on the fence,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： JPM pitch from hospitals? Revenue streams outside of patient care

entertainment

hotspot

knowledge

focus

hotspot

knowledge

EricTokatisco-presidentofinvestmentbankingatCenterviewPartners.CourtesyCenterviewPartnersSANFRANCISC

WSS

FDA advisers vote against ALS treatment from BrainStorm

Medicare Advantage overpayments discussion gets experts fired up

Nonprofit, backed by Microsoft, to certify AI tools in health care

Shingles, which affected Dianne Feinstein, is on the rise

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Gene therapy denied for Afghan refugee whose father aided U.S.

hotspot

leisure time

entertainment

Peter Hotez and the public health issue of online harassment

Hospital chaplains balance Covid safety with patients’ spiritual needs

DIEP, the 'gold standard' of breast reconstruction, is under threat

Ascension's ugly legal battle over care for poor patients in Texas

Bright Health sells Medicare Advantage business to Molina

Researchers use wearables data and AI to predict preterm birth risk

Virginia high school admissions case could be legal follow

Intercept Pharmaceuticals sells itself for less than $1 billion

After affirmative action ruling, medical educators look to 'holistic review'

American taxpayers paid $1.8 trillion in health care costs in 2022

hotspot

Covid vaccines: Private market messier than government rollout

FDA early review: GLP

How the Dana

Sudafed saga points to U.S. issues with evaluating older drugs

Researchers use wearables data and AI to predict preterm birth risk

Medicaid, Medicare dual

knowledge

focus

hotspot

knowledge